Cashing in on the talent crunch

The increased demand for high-quality biopharma executives has translated into an increase in compensation packages across the private biopharma sector, with some stakeholders worrying the trend has gotten out of hand.

According to nine biopharma stakeholders who spoke to BioCentury, the pay packages for private company CEOs have increased substantially in the past three years. And as U.S. investors have increasingly invested in European companies — and those European biotechs have recruited international leadership — the compensation disparity between the U.S. and Europe has also decreased. All stakeholders spoke on condition of anonymity...